Brinker Capital Inc. Has $16.60 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Brinker Capital Inc. boosted its position in Johnson & Johnson (NYSE:JNJ) by 5.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 128,267 shares of the company’s stock after buying an additional 7,103 shares during the quarter. Johnson & Johnson makes up about 0.6% of Brinker Capital Inc.’s portfolio, making the stock its 22nd biggest position. Brinker Capital Inc.’s holdings in Johnson & Johnson were worth $16,595,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in JNJ. Bath Savings Trust Co increased its holdings in Johnson & Johnson by 6.2% during the 2nd quarter. Bath Savings Trust Co now owns 42,275 shares of the company’s stock valued at $5,888,000 after acquiring an additional 2,479 shares in the last quarter. Cox Capital Mgt LLC increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Cox Capital Mgt LLC now owns 19,920 shares of the company’s stock valued at $2,774,000 after acquiring an additional 113 shares in the last quarter. Baystate Wealth Management LLC increased its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. Baystate Wealth Management LLC now owns 29,643 shares of the company’s stock valued at $4,131,000 after acquiring an additional 372 shares in the last quarter. Deane Retirement Strategies Inc. increased its holdings in Johnson & Johnson by 0.7% during the 2nd quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock valued at $1,724,000 after acquiring an additional 85 shares in the last quarter. Finally, Rockland Trust Co. increased its holdings in Johnson & Johnson by 1.6% during the 2nd quarter. Rockland Trust Co. now owns 152,532 shares of the company’s stock valued at $21,245,000 after acquiring an additional 2,425 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE JNJ opened at $129.20 on Wednesday. The company has a market cap of $337.02 billion, a PE ratio of 15.79, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The company has a 50-day simple moving average of $130.47 and a 200-day simple moving average of $134.56.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $0.95 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.94%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

A number of equities research analysts have recently commented on the stock. Raymond James lowered their price target on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Wells Fargo & Co lowered their price target on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a report on Wednesday, October 16th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price target for the company in a report on Thursday, October 17th. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $151.18.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Equal Weight Rating

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit